In 2018, Kato et al. [53] extended the scope of NGS sequencing to include 102,878 patients with different malignancies and found MDM2 amplification in 3.5% of patients; this was present in a small proportion of patients in most tumor types, and 97.6% of these patients had potentially targetable genomic co-alterations, which suggested that appropriately targeted drugs could be designed to target MDM2 amplification-induced HPD. This evidence concerns the gene MDM2 and neoplasm.